Eurosurv. Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canad

[tetano]

• Danuta M Skowronski[SUP]1,2[/SUP] , Erica SY Chuang[SUP]1[/SUP] , Suzana Sabaiduc[SUP]1[/SUP] , Samantha E Kaweski[SUP]1[/SUP] , Shinhye Kim[SUP]1[/SUP] , James A Dickinson[SUP]3[/SUP] , Romy Olsha[SUP]4[/SUP] , Jonathan B Gubbay[SUP]4,5[/SUP] , Nathan Zelyas[SUP]6[/SUP] , Hugues Charest[SUP]7[/SUP] , Nathalie Bastien[SUP]8[/SUP] , Agatha N Jassem[SUP]1,2[/SUP] , Gaston De Serres[SUP]7,9,10[/SUP]

The Canadian Sentinel Practitioner Surveillance Network estimated vaccine effectiveness (VE) during the unusually early 2022/23 influenza A(H3N2) epidemic. Like vaccine, circulating viruses were clade 3C.2a1b.2a.2, but with genetic diversity affecting haemagglutinin positions 135 and 156, and reassortment such that H156 viruses acquired neuraminidase from clade 3C.2a1b.1a. Vaccine provided substantial protection with A(H3N2) VE of 54% (95% CI: 38 to 66) overall. VE was similar against H156 and vaccine-like S156 viruses, but with potential variation based on diversity at position 135.


https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.5.2300043#html_fulltext